Raltegravir, etravirine, and ritonavir-boosted darunavir: A safe and successful rescue regimen for multidrug-resistant HIV-1 infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 3, 2009, Pages 382-386

  Imaz, Arkaitz ^a   Del Saz, Sara Villar ^a   Ribas, M Angels ^b   Curran, Adrian ^a   Caballero, Estrella ^a   Falcó, Vicenç ^a   Crespo, Manel ^a   Ocaña, Inma ^a   Diaz, Marjorie ^a   De Gopegui, Enrique Ruiz ^b   Riera, Melcior ^b   Ribera, Esteban ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Antiretroviral drug resistance; Darunavir; Etravirine; HIV infection; Raltegravir; Salvage treatment

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; RALTEGRAVIR; TIPRANAVIR; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 71049149300     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b17f53     Document Type: Article

References (27)

1. Tozzi V, Zaccarelli M, Bonfigli S, et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antiviral Ther. 2006;11:553-560.
2. Mocroft A, Ledrgerber B, Vilard J, et al. Time to virologic failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis. 2004;190: 1947-1956.
3. Eron JJ. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. J Infect Dis. 2008;197(Suppl 3):S261-S271.
4. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-1178.
5. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
6. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48.
7. Cooper Steigbigel RT, Cooper DA, Kumar PN, et al; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
8. Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 792.
9. Nelson M, Arastéh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005;40:404-412.
10. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368: 466-475.
11. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2008. Top HIV Med. 2008;16:62-68.
12. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47: 266-285.
13. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst. 1993;85:1138-1148.
14. Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS. 2007;21:1449-1455.
15. Croxtall JD, Lyseng-Williamson KA, Perry CM. Raltegravir.Drugs. 2008; 68:131-138.
16. De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determination of resistance to TMC114: pooled analysis of POWER 1, 2, and 3 [Abstract 73]. Antiviral Ther. 2006;11:S83.
17. De Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24:379-388.
18. Delaugerre C, Pavie J, Palmer P, et al. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. AIDS. 2008;22:1809-1813.
19. De Meyer S, Dierynick I, Lauthouwers E, et al. Identification of mutations predictive of a diminished response to darunavir/ritonavir (refined profile): analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET 1 and 2. Program and abstracts of the 6th European HIV Drug Resistance Workshop; March 26-28, 2008; Budapest, Hungary. Abstract 54.
20. Haubrich R, Cahn P, Grinsztejn B, et al; on behalf of DUET-1 Study Group. DUET-1: Week-48 results of a Phase III Randomized, Double-blind, Trial to Evaluate the Efficacy and Safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections February 3-6, 2008; Boston, MA. Abstract 790.
21. Johnson M, Campbell T, Clotet B, et al; on behalf of DUET-2 Study Group. DUET-2: Week-48 results of a Phase III Randomized, Double-blind, Trial to Evaluate the Efficacy and Safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections February 3-6, 2008; Boston, MA. Abstract 791.
22. Vingerhoets J, Buelens A, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antiviral Ther. 2007;12:S34.
23. Vingerhoets J, Peeters M, Azijn H, et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Program and abstracts of the 17th International Drug Resistance Workshop; June 10-14, 2008; Sitges, Spain. Abstract 24.
24. Kumar PN, Cooper DA, Steigbigel RT, et al; for the BENCHMRK-1 and BENCHMRK-2 Study Groups. Efficacy of Raltegravir, an HIV Integrase Inhibitor, in Combination with Regimens Containing Enfuvirtide, Darunavir, or Tipranavir in Patients with Triple-class Resistant Virus: Combined Results from BENCHMRK-1 and BENCHMRK-2. 11th European AIDS Conference. October 24-27, 2007; Madrid, Spain. Poster P7.2/06.
25. Cooper DA, Steigbigel RT, Gatell JM, et al; BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355-365.
26. Hammer SM, Eron JJ, Reiss P, et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
27. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at: www.aidsinfo.nih.gov. Accessed February 20, 2009.